Skip to main content

Table 4 Adverse events

From: Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)

 

N (%) or Median (IQR)

Sensorineural Hearing Loss

6 (12.2%)

 Bilateral

4/6 (66.7%)

 High frequency (> 2000 Hz)

5/6 (83.3%)

 Very high frequency (> 10,000 Hz)

1/6 (16.7%)

 Severe hearing loss

0/6 (0%)

Subjective hearing loss

10 (22%)

Subjective tinnitus

15 (31.9%)

Subjective dizziness

4 (8.5%)

Nephrotoxicity

 Baseline serum creatinine

64 (51, 73)

 Peak serum creatinine

90 (76, 106)

 End of treatment serum creatinine

76 (64, 92)

 Number of patients with nephrotoxicity

10/43 (23.3%)

 % recovery by end of treatment

2/10 (20%)

 GFR < 60 at end of treatment

5 (11.9%)

Proportion of patients who discontinued amikacin prematurely due to AE

21% (17–43%)

  1. GFR Glomerular filtration rate, AE Adverse events